Patents Assigned to Medical Research Institute
  • Method for producing polymers having a preselected activity
    Patent number: 8338107
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: December 25, 2012
    Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLC
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Peptides that home to tumor lymphatic vasculature and methods of using same
    Patent number: 8329859
    Abstract: The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: December 11, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Pirjo Laakkonen, Kimmo Porkka, Jason A. Hoffman, Erkki I. Ruoslahti
  • METHODS FOR DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
    Publication number: 20120276122
    Abstract: Methods for the diagnosis or prognosis of cellular proliferative disorders by detecting expression of PKC in cancer cells or tumor cells are provided herein. Also provided are methods for treating a melanocyte proliferative disorder with agents that modulate the translocational activity of ATF2 and/or PKC? activity.
    Type: Application
    Filed: October 31, 2011
    Publication date: November 1, 2012
    Applicant: Sanford-Burnham Medical Research Institute
    Inventor: Ze'ev Ronai
  • Methods and Compounds Useful to Induce Apoptosis in Cancer Cells
    Publication number: 20120269901
    Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 25, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: John C. Reed, Maurizio Pellecchia
  • APPARATUS AND METHOD FOR TREATING OBSTRUCTIVE SLEEP APNEA
    Publication number: 20120239111
    Abstract: The present invention describes an apparatus, a system and a method for the treatment of obstructive sleep apnea. The treatment involves monitoring the position of the tongue and/or the force exerted by the tongue and electrical stimulation of the hypoglossal nerve to move the tongue into an anterior position or to maintain the tongue in an anterior position.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 20, 2012
    Applicant: Huntington Medical Research Institutes
    Inventor: Douglas B. McCreery
  • Apparatus and method for treating obstructive sleep apnea
    Patent number: 8249723
    Abstract: The present invention describes an apparatus, a system and a method for the treatment of obstructive sleep apnea. The treatment involves monitoring the position of the tongue and/or the force exerted by the tongue and electrical stimulation of the hypoglossal nerve to move the tongue into an anterior position or to maintain the tongue in an anterior position.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: August 21, 2012
    Assignee: Huntington Medical Research Institutes
    Inventor: Douglas B. McCreery
  • COMPOSITIONS RELATING TO A PHOSPHOPROTEIN AND METHODS OF USE
    Publication number: 20120204273
    Abstract: The invention provides methods and compositions for identifying agents that modulates 138-kDa C2 domain-containing phosphoprotein (CDP138) activity or phosphorylation levels both in vivo and in vitro. Also provided are methods and compositions to prolong the survival of neuronal cells, to ameliorate or prevent a condition associated with release of insulin from insulin producing cells and insulin-stimulated glucose metabolism, to inhibiting proliferation of a cancer cell and to inducing cell cycle arrest of a cancer cell.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 9, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventor: Zhen Yue Jiang
  • Methods of differentiating and protecting cells by modulating the p38/MEF2 pathway
    Patent number: 8236563
    Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: August 7, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Stuart A Lipton, Shu-ichi Okamoto
  • ZNF206: A NOVEL REGULATOR OF EMBRYONIC STEM CELL SELF-RENEWAL AND PLURIPOTENCY
    Publication number: 20120196922
    Abstract: We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely down-regulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate genes associated with the pluripotent state, and may lead to the further emergence of genes associated with even more differentiated lineages and phenotypes.
    Type: Application
    Filed: December 5, 2011
    Publication date: August 2, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Evan Yale SNYDER, Rodolfo GONZALEZ
  • TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS
    Publication number: 20120190708
    Abstract: The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes.
    Type: Application
    Filed: July 12, 2010
    Publication date: July 26, 2012
    Applicants: UNIVERSITY OF MARYLAND, BALTIMORE, The Board of Regents of the University of the University of Texas System, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Alexander Mackerell, JR., Hong Zhang, Andrei Osterman, Rohit Kolhatkar
  • Excitatory glycine receptors and methods
    Patent number: 8193315
    Abstract: The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: June 5, 2012
    Assignees: Sanford-Burnham Medical Research Institute, Yale University, The Brigham and Women's Hospital, Inc.
    Inventors: Stuart A. Lipton, Dongxian Zhang, Jon E. Chatterton, Kevin A. Sevarino, Marc Awobuluyi
  • VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
    Patent number: 8188080
    Abstract: Disclosed herein are Vaccinia H1-related (VHR) protein tyrosine phosphatase (PTP) inhibitors that provide a method for treating cancer.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: May 29, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Tomas Mustelin, Lutz Tautz
  • Methods and compositions related to targeting wounds, regenerating tissue, and tumors
    Patent number: 8188220
    Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 29, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tero Jarvinen
  • HMGN2 PEPTIDES AND RELATED MOLECULES THAT SELECTIVELY HOME TO TUMOR BLOOD VESSELS AND TUMOR CELLS
    Publication number: 20120121501
    Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.
    Type: Application
    Filed: October 18, 2011
    Publication date: May 17, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
  • USE OF DYNAMIN RING STABILIZERS
    Publication number: 20120122968
    Abstract: There is provided a method for promoting dynamin ring formation and/or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring formation has particular application in the prophylaxis or treatment of a kidney disease or condition characterized by proteinuria. A dynamin ring stabilizer can be any agent that interacts with dynamin to promote dynamin ring assembly and/or inhibit dynamin ring disassembly. There are also provided methods for prophylaxis or treatment of podocyte dysfunction and/or maintaining or inducing actin cytoskeleton formation in a cell utilizing dynamin ring stabilizers, and for screening a test agent for use as a dynamin ring stabilizer.
    Type: Application
    Filed: May 21, 2010
    Publication date: May 17, 2012
    Applicants: THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL RESEARCH INSTITUTE
    Inventors: Phillip J. Robinson, Sanja Sever
  • Methods and compositions for targeting gC1qR/p32
    Patent number: 8178104
    Abstract: Disclosed are compositions and methods useful for targeting gC1q/p32 receptors. The disclosed targeting is useful for delivering therapeutic and detectable agents to cancerous cells, and to areas of inflammation.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: May 15, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Valentina Fogal
  • Methods of diagnosing and treating migraine
    Patent number: 8163270
    Abstract: The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in the individual's sodium level in the CSF and/or brain extracellular fluid. The CSF sodium level may be based on the sodium concentration in the saliva.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: April 24, 2012
    Assignee: Huntington Medical Research Institutes
    Inventors: Michael G. Harrington, Alfred N. Fonteh
  • METHODS OF DIAGNOSIS AND TREATMENT OF MELANOMA
    Publication number: 20120095078
    Abstract: Methods for the diagnosis or prognosis of melanoma by detecting expression of ATF2 and MITF in melanocytes are provided herein. Also provided are methods of treating a melanocyte proliferative disorder with agents that modulate the transcriptional activity of ATF2 and/or MITF activity.
    Type: Application
    Filed: October 7, 2011
    Publication date: April 19, 2012
    Applicant: Sanford-Burnham Medical Research Institute
    Inventor: Ze'ev Ronai
  • SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY
    Publication number: 20120094922
    Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP.
    Type: Application
    Filed: November 2, 2011
    Publication date: April 19, 2012
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
  • METHOD FOR PREDICTION OF RESPONSE TO RHEUMATOID ARTHRITIS THERAPEUTICS
    Publication number: 20120088678
    Abstract: The present invention is based in part on the identification of a signature marker profile of immune variables to diagnose an immune mediated disease or for prediction of response to an immune mediated disease therapeutic agent. Additionally, the present invention provides methods for the prediction of response to an immune mediated disease therapeutic agent.
    Type: Application
    Filed: September 8, 2011
    Publication date: April 12, 2012
    Applicant: Sanford-Burnham Medical Research Institute
    Inventor: Salvatore Albani